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The purpose of this study was to investigate the bacterial etiology of urinary tract infections in one of the busiest hospitals of
Lebanon and to examine the epidemiologic and microbiologic properties of Escherichia coli isolated from urinary tract infections
of Lebanese patients over a 10-year period. Methods. This retrospective study analyzed the data generated between 2000 and
2009 (10,013 Gram-positive and Gram-negative bacteria). Bacterial identiﬁcation was based on standard culture and biochemical
characteristics of isolates. Antimicrobial susceptibility was tested by the disk diﬀusion method, and ESBL production was detected
by synergy with third-generation cephalosporins and amoxiclav. Results. E. coli was the most frequent isolate throughout the ten
years (60.64% of the total isolates). It was followed by Klebsiella pneumoniae and Proteus sp., Pseudomonas aeruginosa, Enterococcus
sp.,a n dStreptococcus agalactiae. E. coli occurred more frequently in women (69.8%) than in men (61.4%). The lowest percentage
of susceptibility of E. coli was manifested against piperacillin and ampicillin. An increase in the production of ESBL was observed
(2.3%in2000to16.8%in2009).Conclusions.Theetiologyofurinarytractinfectionsandtheirsusceptibilityproﬁlesareimportant
to be evaluated in countries like Lebanon where a severe misuse of antibiotics at all levels is observed.
1.Introduction
Urinary tract infections (UTIs) are one of the most common
infectious diseases [1–3]. They may be symptomatic or
asymptomatic, and either type of infection can result in
serious sequelae if not appropriately treated [4]. Although
diﬀerent causative agents can be responsible for UTIs, bacte-
ria are the major cause being responsible for more than 95%
of UTI cases [5]. In this context, E. coli is the most prevalent
organism and is solely responsible for the majority of these
infections.Anaccurateandpromptdiagnosisisimportantin
shortening the disease course and for preventing the ascent
of the infection to the upper urinary tract [6]. Treatment
of UTI is often started empirically. UTIs are often treated
with diﬀerent broad-spectrum antibiotics when one with
a narrow spectrum of activity may be appropriate because
of concerns about infection with resistant organisms, and
antimicrobial susceptibility testing of the urinary pathogens
constitutes the basis for antibiotic therapy. However, in view
of the increasing bacterial resistance, regular monitoring of
resistance patterns is necessary to improve guidelines for
empirical antibiotic therapy [6–8]. The present study aims at
analyzing the infectious epidemiology of UTIs in a general
university hospital located in Beirut over a period of ten
years. In addition, it examines the susceptibility proﬁles of
E. coli between 2000 and 2009.
2.MaterialandMethods
2.1. Study Design. This is a retrospective study conducted
at the Microbiology section of the Medical Laboratories
of the Saint George Hospital-University Medical Center in
Beirutandcoveringtenyears(2000to2009). Thepopulation
included all in- and outpatients with documented UTI. This
included 10,013 diﬀerent Gram-positive and Gram-negative
bacteria in addition to Candida albicans and Candida sp.2 Chemotherapy Research and Practice
There were 6,708 (66.99%) samples from female patients
and 3,305 (33.01%) from male patients. Adult patients were
sampled by clean catch midstream urine, and children aged
lessthan3yearsweresampledusingsterileurinebags.Onlya
singlepositivecultureperpatientwasincludedintheanalysis
within the period of three months.
2.2. Isolation and Identiﬁcation of Organisms. Samples for
urine culture were tested within half an hour of sampling.
All samples were inoculated on blood agar as well as Mac
Conckey agar and incubated at 37◦C for 24 hours, and
for 48 hours in negative cases. A specimen was considered
positive for UTI in the light of the number of yielded
colonies (≥105 cfu/mL) and the cytology of the urine
through microscopic detection of bacteriuria and PMNs (≥8
leukocytes/mm3). However, lower colony counts associated
with signiﬁcant pyuria or low PMN count associated with
signiﬁcant colony counts was considered and analyzed in the
light of the clinical picture and the patient’s immunological
status. Bacterial identiﬁcation was based on standard culture
and biochemical characteristics of isolates.
Gram-negative bacteria were identiﬁed by standard bio-
chemical tests [5, 6]. Gram-positive microorganisms were
identiﬁed with the corresponding recommended laboratory
tests.
2.3. Susceptibility Testing. Antimicrobial susceptibility of E.
coli was tested by the disk diﬀusion method according to the
CLSI recommendations, using the Mueller-Hinton agar [6].
Antimicrobial agents tested were ampicillin, amoxicillin-cla-
vulanic acid, aztreonam, cephalothin, cefoxitin, cefuroxime,
cefotaxime, ceftriaxone, ceftazidime, ceﬁpime, piperacillin,
piperacillin-tazobactam, imipenem, gentamycin, tobramy-
cin, norﬂoxacin, ciproﬂoxacin, trimethoprim-sulfametho-
xazole, and tetracycline. The CLSI-ESBL phenotypic conﬁr-
matory test with ceftazidime, cefotaxime, ceftriaxone, and
ceﬁxime was performed for all the isolates by disk diﬀusion
method on the Mueller-Hinton agar plates with and without
10μgofamoxiclav.Susceptibilitytestresultswereinterpreted
accordingtothecriteriaestablishedbytheClinical&Labora-
toryStandardInstitute(CLSI).Aminimumof5mmincrease
in the zone of diameter of third-generation cephalosporins,
tested in combination with amoxiclav versus its zone when
tested alone, was considered indicative of ESBL production.
E. coli ATCC 25922 was used as ESBL-negative and K. pneu-
moniae 700603 was used as ESBL-positive reference strain.
Statistical analysis: variables were expressed as percentages.
3. Results
Overa10-yearperiod, atotalof10,013 positive urine isolates
including 6,071 E. coli were analyzed.
Tables 1 and 2 show the microorganisms most frequently
isolated from these positive urine cultures. As expected, E.
coli was the most frequent isolate throughout the ten years
(average of 60.64% of the total isolates). It was followed by
Klebsiellapneumoniaewhererateofisolationrangedbetween
6.1and9.9%.Thenextmostfrequentlyisolatedbacteriawere
Proteus sp., Pseudomonas aeruginosa, Enterococcus sp., and
Streptococcus agalactiae. Candida albicans and Candida sp.
were commonly isolated; however, their clinical signiﬁcance
was not always evident. If Candida and minor bacterial
isolates are not included, Gram-negative bacteria accounted
for 92% of the UTI, while Gram-positive infections were
responsible only for 8%.
Analysis of the results according to patient gender (not
shown) indicated that although E. coli is the predominant
isolated pathogen from both sexes, it occurred more fre-
quently in women (69.8% in women compared to 61.4% in
men.) The trend of infectious etiology in the population did
not really diﬀer over the 10-year period.
The percentages of susceptibility (and subsequently of
nonsusceptibilityincludingbothresistantandintermediately
resistant strains) of E. coli isolates to the panel of antibiotics
which are commonly used to treat Escherichia infections are
shown in Table 3. The lowest percentage of susceptibility
was manifested against piperacillin (between 9 and 24%)
followed by ampicillin (between 26 and 38%), whereas an
absolute susceptibility was observed with imipenem (100%).
In general, the urinary isolates showed a slightly better
susceptibilityproﬁleincomparisontoallthehospitalisolates
of E. coli. Over the successive years, the susceptibility to
cephalosporins, including generations 3 and 4, tends to
decrease; this is coupled by an increase in the production of
ESBL as shown in Table 4 where ESBL production goes from
2.3% in 2000 to 16.8% in 2009 for the urinary isolates.
Table 5 shows the susceptibility proﬁles of ESBL produc-
ing E. coli to families of antibiotics other than beta-lactams.
Tigecycline, amikacin, and piperacillin-tazobactam seem to
have the highest antibacterial activity on these organisms.
Table 6 shows the percentages of simultaneous resistance
in the urinary isolates of E. coli to various families of
antimicrobial agents.
4. Discussion
This study shows the distribution of microbial species and
antibiotic susceptibility patterns of E. coli isolated from
Lebanese patients with UTIs. Saint George Hospital is a
300-bed hospital located in Beirut; however, it is one of
the busiest hospitals in the country and receives patients
from diﬀerent areas of Lebanon. In this retrospective
study, no clinical data are provided, and this constitutes
by itself a limitation. Subsequently, important information
related to symptomatic versus asymptomatic, complicated
versusuncomplicatedUTI,andhealth-care-associatedversus
catheter-related UTIs could not be addressed and discussed.
The majority of pathogens were isolated from women
(69.8%). It has been extensively reported that adult women
have a higher prevalence of UTI than men, principally owing
to anatomic and physical factors [9].
Antibiotic resistance is a major clinical problem in
treating infections caused by these microorganisms. The
resistance to the antimicrobials has increased over the years.
Resistance rates vary from country to country [10]. In
Lebanon,thereisanevidenceforincreaseinESBLproducingChemotherapy Research and Practice 3
Table 1: The organisms most commonly isolated from Lebanese patients with UTI between 2000 and 2004 at Saint George Hospital
University Medical Center, Beirut.
The microorganisms most commonly isolated from Lebanese patients with UTI between 2000 and 2004
2000 2001 2002 2003 2004
Nb % Nb % Nb % Nb % Nb %
Acinetobacter sp. 3 0.5 4 0.5 2 0.2 0 0.0 14 1.3
Candida albicans 15 2.4 12 1.6 23 2.4 26 2.4 31 2.9
Candida sp. 16 2.5 22 2.9 28 2.9 47 4.3 34 3.1
Citrobacter sp. 6 0.9 11 1.5 19 2.0 17 1.5 15 1.4
Enterobacter sp. 4 0.6 12 1.6 14 1.5 6 0.5 16 1.5
Enterococcus faecalis 17 2.7 18 2.4 28 2.9 48 4.4 20 1.9
Enterococcus faecium 6 0.9 18 2.4 20 2.1 30 2.7 35 3.2
Escherichia coli 395 62.5 440 58.3 575 59.8 637 57.9 661 61.1
Klebsiella sp. 48 7.6 75 9.9 59 6.1 85 7.7 79 7.3
Morganella morganii 5 0.8 4 0.5 11 1.1 14 1.3 14 1.3
Proteus sp. 45 7.1 50 6.6 72 7.5 74 6.7 65 6.0
Pseudomonas aeruginosa 30 4.7 38 5.0 45 4.7 35 3.2 51 4.7
Pseudomonas sp. 0 0.0 2 0.3 1 0.1 1 0.1 0 0.0
Staphylococcus aureus 3 0.5 6 0.8 3 0.3 7 0.6 9 0.8
Staphylococcus
saprophyticus 6 0.9 7 0.9 5 0.5 2 0.2 3 0.3
Streptococcus agalactiae 20 3.2 15 2.0 14 1.5 25 2.3 18 1.7
Streptococcus, Group D 1 0.2 2 0.3 4 0.4 1 0.1 6 0.6
Other minor organisms 12 1.9 19 2.5 38 4.0 45 4.1 10 0.9
Total isolates 632 755 961 1100 1081
Table 2: The organisms most commonly isolated from Lebanese patients with UTI between 2000 and 2004 at Saint George Hospital
University Medical Center, Beirut.
The microorganisms most commonly isolated from Lebanese patients with UTI between 2005 and 2009
2005 2006 2007 2008 2009
Nb % Nb % Nb % Nb % Nb %
Acinetobacter sp. 19 1.9 14 1.2 18 1.6 16 1.3 5 0.5
Candida albicans 14 1.4 37 3.3 27 2.4 29 2.4 25 2.5
Candida sp. 29 2.9 57 5.1 34 3.0 31 2.6 35 3.5
Citrobacter sp. 15 1.5 18 1.6 19 1.7 16 1.3 9 0.9
Enterobacter sp. 16 1.6 22 2.0 14 1.2 19 1.6 6 0.6
Enterococcus faecalis 14 1.4 15 1.3 20 1.8 14 1.2 15 1.5
Enterococcus faecium 32 3.2 25 2.2 34 3.0 34 2.8 6 0.6
Escherichia coli 609 60.2 711 63.4 688 60.7 727 60.0 628 62.5
Klebsiella sp. 92 9.1 84 7.5 100 8.8 118 9.7 90 9.0
Morganella morganii 13 1.3 6 0.5 10 0.9 24 2.0 7 0.7
Proteus sp. 57 5.6 53 4.7 70 6.2 73 6.0 63 6.3
Pseudomonas aeruginosa 39 3.9 27 2.4 40 3.5 44 3.6 41 4.1
Pseudomonas sp. 0 0.0 6 0.5 0 0.0 6 0.5 3 0.3
Staphylococcus aureus 70 . 740 . 460 . 540 . 3 1 0 1 . 0
Staphylococcus
saprophyticus 0 0.0 5 0.4 1 0.1 2 0.2 3 0.3
Streptococcus agalactiae 27 2.7 14 1.2 16 1.4 16 1.3 8 0.8
Streptococcus, Group D 1 0.1 1 0.1 1 0.1 0 0.0 1 0.1
Other minor organisms 28 2.8 23 2.0 36 3.2 38 3.1 50 5.0
Total isolates 1012 1122 1134 1211 10054 Chemotherapy Research and Practice
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Table 4:ESBLproductionin E.colicollectedfromLebanesepatientsbetween2000and2009attheSaintGeorgeHospitalUniversityMedical
Center, Beirut. U: urinary isolates, NU: nonurinary isolates.
ESBL production in E. coli isolated between 2000 and 2009
2000 2001 2002 2003 2004
Isolates All U NU All U NU All U NU All U NU All U NU
Number of isolates 620 395 225 697 440 257 901 699 202 1221 637 584 1094 661 433
% of ESBL 2.3 2.1 2.3 4 3.9 4.3 9.8 9.9 9.5 13.6 14.5 12.1 12.9 11.0 14.1
2005 2006 2007 2008 2009
Isolates All U NU All U NU All U NU All U NU All U NU
Number of isolates 998 609 389 1072 711 361 1049 688 361 1098 727 371 1011 628 383
% of ESBL 20.3 15.7 26.1 17.4 15.6 19.1 19.45 19.2 19.8 19.4 17.1 22.0 18.6 16.8 21.8
Table 5: Susceptibility proﬁles of ESBL producing E. coli collected from Lebanese patients between 2005 and 2009 at the Saint George
Hospital-University Medical Center, Beirut.
Percentages of susceptibility of ESBL producing E. coli
Antibacterial agent
Year Isolates Amikacin Cefoxitin Gentamycin Pip + Tazo TSM Tigecycline Ciproﬂoxacin
2005
All 90.5 85.6 29.8 97.6 39.4 ND 21.1
Urinary 92.3 87.6 35.2 97.5 41.1 ND 16.4
Nonurinary 88.2 83.5 25.1 97.8 37.1 ND 17.9
2006
All 97.9 80.7 27.3 93.3 24.1 ND 17.6
Urinary 95.6 84.4 33.5 94.1 40.8 ND 18.8
Nonurinary 98.3 76.9 22.1 93.5 18.9 ND 16.5
2007
All 93.6 81.4 30.1 92.2 23.5 89.6 23.1
Urinary 91.2 87.5 22.4 89.9 36.8 91.2 25.7
Nonurinary 90.2 75.6 36.8 95.4 41.3 93.2 19.1
2008
All 94.2 80.6 27.8 94.1 25.6 87.4 18.8
Urinary 89.1 82.4 24.4 87.9 26.6 91.4 21.1
Nonurinary 97.3 77.1 32.2 98.8 23.9 82.1 15.5
2009
All 93.6 83.4 30.8 94.2 19.5 91.6 19.6
Urinary 94.6 84.5 36.1 96.6 25.4 94.4 19.5
Nonurinary 91.8 82.2 26.3 92.2 10.6 89.9 19.2
Table 6: Multiple resistance of urinary isolates of E. coli.
Percentage of resistance proﬁles
Resistance proﬁle of urinary E. coli 2005 2006 2007 2008 2009
Resistant to aminoglycosides and ﬂuoroquinolones 3.2 2.6 3.1 3 3.7
Resistant to 3rd-Generation cephalosporins and ﬂuoroquinolones 3.6 3 4.9 8.2 9.6
Resistant to 3rd-Generation cephalosporins and aminoglycosides 3.9 3.4 3.5 2.5 3.1
Resistant to 3rd-Generation cephalosporins, aminoglycosides, and
ﬂuoroquinolones 8.7 9 9.8 13.8 7.3
Enterobacteriaceae. This was previously reported in our
hospital as well as in other institutions in the country [11–
15]
In this study, E. coli accounted for approximately 61%
of all clinically signiﬁcant urinary isolates and 76.8% of
all Enterobacteriaceae. This is consistent with the ﬁndings
of previous studies in which E. coli was the predominant
pathogen isolated from patients with UTIs [16, 17]. The rate
of isolation of Klebsiella pneumoniae might be described as
high when compared to other studies [16, 17]; however, this
can be explained by the fact that our study includes both
hospital and acquired UTI.
E. coli isolates from urinary infections show a similar
pattern of susceptibility to those isolated from all body site6 Chemotherapy Research and Practice
infections although with a more enhanced susceptibility per-
centages. Aminopenicillins do not constitute a therapeutic
option inthis population; eventhecombinationamoxicillin-
clavulanic acid does not seem to oﬀer important alternative
for treatment. In view of the increasing ESBL production, all
cephalosporins activities are aﬀected and challenged by these
inactivating enzymes. Imipenem remains the only antibiotic
with 100% of susceptibility.
It is pretty alarming to note that between 7.3 and 13.8%
of the urinary isolates of E. coli show simultaneous resistance
to third-generation cephalosporins, aminoglycosides, and
ﬂuoroquinolones. A genetic investigation on these isolates
should be performed in order to identify the mechanisms of
resistance and discover whether they are correlated to each
other or independently occurring.
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